Britons switch to dual-action asthma inhalers in major treatment shift
Updated
Updated · The Times · May 6
Britons switch to dual-action asthma inhalers in major treatment shift
12 articles · Updated · The Times · May 6
NICE said 1.09 million patients used AIR and MART inhalers without any blue SABA use between October and December last year.
The 2024 guidance followed evidence that blue inhaler overuse can worsen asthma and raise risks of attacks, hospital admissions and death by masking underlying inflammation.
NICE estimates every 10,000 people switching could prevent 1,133 GP visits, 144 A&E attendances and 80 hospital admissions annually, though clinicians say inappropriate SABA prescribing persists.
Why are doctors warning against the blue asthma inhaler that millions have relied on for decades?
If new asthma treatments are saving lives in Europe, why do barriers still limit access in the United States?
The End of the Blue Inhaler: How NICE’s 2026 Guidelines Are Revolutionizing Asthma Care
Overview
In 2026, NICE issued a crucial warning that over-reliance on blue SABA inhalers worsens asthma by masking inflammation and increasing severe attacks. This has accelerated a shift in the UK towards combination inhalers using Anti-Inflammatory Reliever (AIR) and Maintenance and Reliever Therapy (MART), which treat inflammation while providing relief. These new therapies improve asthma control, reduce severe attacks, and enhance quality of life. However, patient resistance due to concerns about steroids and misinformation remains a challenge. Supported by initiatives like the Respiratory Transformation Partnership, this shift not only saves NHS costs by reducing emergency care but also marks a life-saving transformation in asthma management.